Market news

WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity

Dyne Therapeutics announced it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen for myotonic dystrophy type 1 at upcoming World Muscle Society and AANEM meetings in late September and early October 2026. The breadth of new functional and safety data, alongside details from a matched natural history cohort and a fully enrolled registrational expansion cohort, adds depth to Dyne’s emerging clinical story in DM1. We’ll now examine how...

Tipranks Press Release.

Dyne Therapeutics lead asset z-rostudirsen faces regulatory and confirmatory risks, with FDA approval likely. Find out why DYN stock is a buy.

Dyne Therapeutics (DYN) has an average rating of buy and mean price target of $37.27, according to a

Dyne Therapeutics (DYN) investment thesis remains intact despite a setback for Novartis (NVS) in a p

Dyne Therapeutics (DYN) has an average rating of buy and mean price target of $37.27, according to a

- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort - - Dyne also intends to provide the mean baseline value for video hand opening time (vHOT) in the ACHIEVE registrational expansion cohort (REC) in conjunction with these presentations - - Topline data from the ACHIEVE REC are on track for Q1 2027 - WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.

Dyne Therapeutics (NASDAQ:DYN) shares fell 31. 0% to $16.

Novartis stock sinks 13% after del-desiran phase 3 trial failed primary endpoints, sparking biotech selloff.

- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD - WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering funct

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference, fireside chat on Friday, September 11, 2026 at 10:20 a.m. ET in New York, NYMorgan Stanley 24th Annual Global Healthcare Con

WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 11 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Biogen Inc (BIIB-Q) from The Globe and Mail including charting and trades.

Dyne Therapeutics (DYN) has an average rating of buy and mean price target of $39.67, according to a

- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment of 71 participants in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in DM1; topline data planned for Q1 2027 - - Investigational New Drug (IND) Application cleared by FDA for DYNE-302 in FSHD - - Expected cash runway into Q2 2028 - WALTHAM, Mass., July 29, 2026 (GLOBE NEW

- Company’s third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease - WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IND ap

Dyne Therapeutics (DYN) said Tuesday the US Food and Drug Administration cleared its investigational

WALTHAM, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 12 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,045,000 shares of its common stock at a public offering price of $20.50 per share, which includes 2,745,000 shares issued upon the exercise in full by the underwriters of their

Dyne Therapeutics (DYN) is back in focus after pricing an upsized follow on equity offering of 18,300,000 common shares at $20.50 each, raising about $375 million in gross proceeds. See our latest analysis for Dyne Therapeutics. Despite the short term pressure from the discounted offering price, with a 1 day share price return of 2.60% lower and a 7 day share price return of 3.25% lower, Dyne Therapeutics still shows strong momentum. The 30 day share price return is 11.21%, the 90 day share...

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.